dr
thoma
nhsnet
link
coagulopathi
also
thrombot
risk
signific
studi
publish
patient
admit
intens
care
unit
icu
klok
et
al
describ
cohort
patient
icu
depart
netherland
found
cumul
incid
thrombot
complic
includ
pulmonari
emboli
pe
deep
vein
thrombosi
dvt
cathet
relat
thrombos
arteri
thrombos
patient
studi
receiv
thromboprophylaxi
low
molecular
weight
heparin
cui
et
al
describ
cohort
patient
singl
centr
icu
china
develop
venou
thromboembol
vte
howev
none
receiv
chemic
thromboprophylaxi
third
studi
french
multicentr
icu
studi
patient
demonstr
preval
thrombosi
occur
despit
prophylact
therapeut
anticoagul
describ
result
observ
studi
examin
thrombot
complic
patient
admit
addenbrook
hospit
icu
tertiari
centr
cambridg
unit
kingdom
studi
full
approv
trust
research
develop
depart
patient
consent
requir
observ
studi
composit
endpoint
pe
dvt
includ
line
associ
arteri
thrombosi
myocardi
infarct
stroke
peripher
arteri
embol
index
date
date
icu
admiss
censor
date
discharg
hospit
death
transfer
royal
papworth
hospit
run
region
ecmo
servic
thrombosi
whatev
soonest
patient
investig
pe
base
clinic
suspicion
eg
unexplain
hypotens
hypoxia
felt
disproportion
pneumonia
ct
pulmonari
angiogram
ctpa
line
associ
thrombosi
due
local
symptom
arteri
ischaemia
base
clinic
symptom
troponin
electrocardiogram
abnorm
suggest
myocardi
ischaemia
patient
radiolog
confirm
thrombosi
includ
case
myocardi
infarct
coronari
angiographi
total
patient
confirm
nasopharyng
swab
polymeras
chain
reaction
includ
case
centr
admit
icu
medic
note
epic
wi
usa
interrog
statist
analysi
perform
use
microsoft
excel
microsoft
redmond
wa
usa
r
programm
version
r
core
team
r
languag
environ
statist
comput
r
foundat
statist
comput
vienna
austria
patient
characterist
present
tabl
median
number
day
observ
rang
censor
date
patient
die
patient
transfer
royal
papworth
hospit
patient
still
hospit
icu
either
discharg
remain
hospit
medic
ward
patient
transfer
district
gener
hospit
icu
patient
vte
risk
assess
use
depart
health
tool
per
guidanc
nation
institut
health
care
excel
guidelin
prescript
prophylact
dalteparin
adjust
weight
renal
function
tabl
patient
haemofiltr
receiv
unfraction
heparin
dialysi
circuit
also
prophylact
dalteparin
filtrat
circuit
thrombos
system
unfraction
heparin
use
clinician
discret
observ
ongo
problem
one
patient
treat
pe
empir
radiolog
confirm
therapeut
low
molecular
weight
heparin
includ
cumul
incid
analysi
total
patient
pe
one
requir
thrombolysi
alteplas
haemodynam
instabl
myocardi
infarct
line
associ
thrombosi
jugular
vein
cumul
incid
estim
vte
confid
interv
arteri
thrombosi
ci
composit
outcom
ci
later
shown
figur
patient
ctpa
patient
repeat
studi
therefor
posit
pe
pe
subsegment
segment
multipl
segment
main
pulmonari
arteri
none
patient
develop
thrombosi
histori
either
activ
cancer
vte
limit
studi
singlecentr
retrospect
studi
reflect
local
practic
investig
patient
perform
clinic
suspicion
thrombosi
rather
surveil
scan
lower
limb
patient
systemat
examin
evid
lower
limb
line
associ
dvt
daili
patient
haemofiltr
receiv
unfraction
heparin
dialysi
circuit
also
prophylact
dalteparin
note
due
haemofiltr
circuit
block
patient
receiv
intraven
heparin
systemat
record
data
one
patient
treat
pe
empir
therapeut
low
molecular
weight
heparin
j
u
r
n
l
p
r
e
p
r
f
confirm
radiolog
includ
cumul
incid
analysi
patient
die
one
confirm
pe
one
neg
ctpa
eight
unknown
pe
present
like
underestim
thrombosi
rate
patient
systemat
imag
autopsi
would
requir
gather
rate
pe
deceas
patient
imag
conclud
concern
thrombot
risk
patient
howev
compar
rate
vte
seen
critic
ill
patient
condit
concern
microvascular
thrombosi
whether
anticoagul
would
benefit
intensifi
would
welcom
trial
determin
whether
escal
dose
anticoagul
would
benefit
inpati
light
find
icu
hospit
switch
twice
daili
prophylact
dalteparin
wtspeaker
fee
pfizer
bayer
advisori
board
daiichi
sanyo
mb
speaker
fee
stago
advisori
board
novarti
cosmopharma
werfen
ksmember
nice
ng
vte
guidelin
group
receiv
speaker
fee
actelion
author
declar
relev
conflict
interest
wtcollect
data
wrote
first
draft
design
studi
jvcollect
data
mbwrote
first
draft
data
analysi
aj
mr
es
ks
alintellectu
input
author
intellectu
input
approv
final
draft
manuscript
